Company
Galecto, Inc.
Headquarters: Copenhagen, Denmark
Employees: 28
CEO: Dr. Hans T. Schambye
Market Cap
$65.5 Million
USD as of July 1, 2023
Galecto, Inc. Categories
Denmark
languages
Healthcare
languages
Biotechnology
Denmark Healthcare
Denmark Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
|
Novo Nordisk
|
$329.83 B |
Vertex Pharmaceuticals Incorporated
|
$88.79 B |
CSL Limited
|
$85.00 B |
| Marinomed Biotech AG | $84.73 B |
|
Regeneron Pharmaceuticals, Inc.
|
$78.88 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
|
UnitedHealth Group
|
$428.70 B |
|
Lilly
|
$417.05 B |
|
Johnson & Johnson
|
$412.24 B |
|
Novo Nordisk
|
$329.83 B |
|
Merck
|
$275.82 B |
Detailed Description
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.
Stocks & Indices
Galecto, Inc. has the following listings and related stock indices.
Stock: NASDAQ: GLTO